Core Viewpoint - The stock of WuXi AppTec experienced a decline of 4.41% on October 17, with a trading volume of 3.887 billion yuan and a market capitalization of 288.231 billion yuan [1] Group 1: Company Overview - WuXi AppTec is a leading international open-access capability and technology platform providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2] - The company is a domestic leader in the pharmaceutical outsourcing industry and one of the earliest integrated CRO and CMO companies in China, with a management team holding over 200 authorized and pending patents [2] - The main business involves the discovery, research, and production of small molecule chemical drugs, offering a full-spectrum integrated platform service to global pharmaceutical companies [2][7] Group 2: Financial Performance - For the first half of 2025, WuXi AppTec achieved operating revenue of 20.799 billion yuan, representing a year-on-year growth of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, which is a 101.92% increase year-on-year [7] - The company’s revenue composition includes 78.37% from chemical business, 12.93% from testing services, 6.02% from biological services, and 1.90% from other supplementary services [7] Group 3: Market Dynamics - The company benefits from a high overseas revenue ratio of 78.67%, which is positively impacted by the depreciation of the Chinese yuan [3] - The stock has seen a net outflow of 2.92 million yuan from major funds today, with a continuous reduction in major fund holdings over the past two days [4][5] Group 4: Technical Analysis - The average trading cost of the stock is 94.96 yuan, with recent rapid outflows of shares suggesting a recommendation for portfolio adjustment [6] - The current stock price is approaching a resistance level of 97.20 yuan, indicating a potential for a pullback unless this resistance is broken [6]

Market Performance - The market experienced a downward trend, with the Shanghai Composite Index falling by 1.95% to 3839.76 points, marking a weekly decline of 1.47%. The Shenzhen Component Index dropped by 3.04%, with a weekly decline of 4.99%, while the ChiNext Index fell by 3.36%, with a weekly decline of 5.71% [1] ETF Performance - Gold ETFs and gold-related investments saw significant gains, with increases exceeding 11%, leading the market. Other ETFs, including bank and coal ETFs, rose over 4%, while several financial ETFs gained more than 3% [2] Gold Market Insights - The total market capitalization of gold has surpassed $30 trillion, positioning it as a leading asset in the global market. This value exceeds the combined market capitalization of the top ten stocks, which stands at $25.3 trillion [2][3] Banking Sector Trends - The banking sector has shown strength throughout the year, experiencing a correction after reaching a peak in July, followed by a rebound since October [4] - Several bank shareholders and executives have announced plans to increase their holdings in their respective banks, indicating confidence in long-term investment value [5][6] Investment Strategies - A "barbell strategy" is recommended for investment, focusing on: 1. Offensive sector - Technology growth, driven by policies and technological advancements in AI and related fields [7] 2. Defensive sector - High dividend and quality leading companies, which are attractive in a low-interest-rate environment [7] Market Outlook - The A-share market is expected to remain in an upward cycle, supported by low interest rates, improving cash flows for listed companies, and ongoing government support for technology innovation [10][9]

Core Viewpoint - The stock of JiuZhiTang has experienced fluctuations, with a recent decline of 2.08% and a year-to-date increase of 29.32%, indicating volatility in investor sentiment and market performance [1][2]. Company Overview - JiuZhiTang Co., Ltd. was established on May 12, 1999, and listed on June 28, 2000. The company is based in Beijing and Changsha, specializing in the research, production, and sales of traditional Chinese medicine, biological pharmaceuticals, and cardiovascular drugs [2]. - The revenue composition of JiuZhiTang includes prescription drugs (50.27%), OTC products (46.11%), other products (2.50%), health products (0.92%), and additional categories (0.20%) [2]. Financial Performance - For the first half of 2025, JiuZhiTang reported revenue of 1.265 billion yuan, a year-on-year decrease of 24.71%, and a net profit attributable to shareholders of 144 million yuan, down 29.71% compared to the previous year [2]. - The company has distributed a total of 4.364 billion yuan in dividends since its A-share listing, with 935 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, JiuZhiTang had 50,500 shareholders, an increase of 25.14% from the previous period, with an average of 13,739 circulating shares per shareholder, a decrease of 20.09% [2]. - The top ten circulating shareholders include a new entrant, Qianhai Kaiyuan Steady Growth Mixed Fund, holding 1.996 million shares [3]. Market Activity - JiuZhiTang's stock has been on the龙虎榜 (a stock trading list in China) three times this year, with the most recent appearance on July 10, where it recorded a net buy of -48.5516 million yuan [1].

Group 1 - The medical sector experienced volatility, with the largest medical ETF in A-shares (512170) dropping over 2% in the afternoon, with real-time transactions exceeding 490 million yuan [1] - The ETF's latest scale is 25.73 billion yuan, ranking first among similar ETFs [1] - Notable declines were observed in constituent stocks, with Sanbo Brain Science falling over 6%, and other companies like Yingke Medical and Nanwei Medical dropping more than 4% [1] Group 2 - Ping An Securities indicated that the bidding environment for medical devices will remain favorable in 2025, with strong demand for ultrasound, CT, and MRI equipment driven by policy incentives [3] - The pharmaceutical and biotechnology sectors are currently affected by policy disruptions, but the long-term industry trend remains unchanged, with Chinese innovative drug companies gaining global competitiveness [3] - The medical ETF (512170) passively tracks the CSI Medical Index, with its top ten weighted stocks including WuXi AppTec, Mindray Medical, and others [3]

Core Viewpoint - Zhaoli Pharmaceutical's stock price has shown a year-to-date increase of 26.83%, with recent trading activity indicating a slight decline of 2.04% on October 17, 2023, reflecting market volatility and investor sentiment [1]. Financial Performance - For the first half of 2025, Zhaoli Pharmaceutical reported a revenue of 1.599 billion yuan, representing a year-on-year growth of 11.99%. The net profit attributable to shareholders was 374 million yuan, marking a 26.16% increase compared to the previous year [2]. - Cumulatively, since its A-share listing, Zhaoli Pharmaceutical has distributed a total of 1.442 billion yuan in dividends, with 942 million yuan distributed over the last three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Zhaoli Pharmaceutical reached 38,600, an increase of 0.92% from the previous period. The average number of circulating shares per shareholder decreased by 0.91% to 15,627 shares [2]. - Notable new institutional shareholders include China Europe Responsibility Investment Mixed A and Innovation Medicine, both entering the top ten circulating shareholders [3].

Report Industry Investment Rating No information provided in the content. Core Viewpoints of the Report - Huashang Fund's Zhang Mingxin is a fund manager with profound research background and a systematic investment framework, managing a total fund size of 4.241 billion yuan as of the end of the second quarter of 2025. His investment philosophy of "value as the foundation, trend as the wings" enables him to maintain strong adaptability and competitiveness in complex market environments [2]. - Zhang Mingxin's two current public - offering funds, Huashang Equal - Growth and Huashang Advantage Industry, have excellent performance. As of September 22, 2025, their excess returns relative to similar funds reached 67.07% and 57.18% respectively, and their performance rankings are among the top 0.86% and 1.25% in similar funds [2]. - Another fund he manages, Huashang Zhiyuan Return, is a floating - rate fund, which reflects the confidence of Huashang Fund and the fund manager in its future performance [3]. - The product YDZC - Taihe Preferred No. 2 managed by Zhang Mingxin at Yingda Insurance Asset Management achieved an excess return of 75.05% relative to the CSI 300 index. From early 2021 to early 2025, it achieved a positive return of 44.01% while the market declined by 31.04% [3]. - Based on the fund TM attribution analysis, Zhang Mingxin shows significant and positive stock - selection ability and strong adaptability under different market conditions and value - growth style dominance [3]. - Zhang Mingxin is long - term optimistic about the AI industry trend, believing that overseas computing power is the starting point of a long - cycle, and AI applications are reshaping the world. He also believes that there may be systematic investment opportunities in new consumption, innovative drugs, and military trade and defense industries [4]. Summary According to the Directory 1. Investment Philosophy Kernel: Value as the Foundation, Trend as the Wings 1.1 Investment Framework - Zhang Mingxin believes that investment is to find the paradigm of "stocks will rise in this situation", and the essence of stock - selection is to find the market's feedback mechanism to information. He has formed an investment philosophy of industry trend investment driven by value [9]. - Value investment aims to achieve the highest - probability investment paradigm. He believes that value = deep value + growth value + gaming value, and mainly earns from company growth value and partial deep - value regression. He participates in different stages of the industry cycle [11]. - The core investment concept is industry trend investment driven by value, which can balance short - term and long - term performance. It requires comprehensive value assessment, cross - industry tracking, and finding alpha targets in booming industries. Zhang Mingxin is good at rotating investments in multiple industries [13]. 1.2 Views on the Market - In 2025, the market first strengthened due to the global large - model equalization wave led by DeepSeek, then declined due to the global trade war initiated by the US, and finally gradually returned to trading fundamentals after a series of policies [17][18]. - Zhang Mingxin continued to follow the investment philosophy of industry trend investment based on value. After the market decline in early April, he adjusted his positions and increased the allocation of overseas computing power sectors in May, achieving good returns [18]. - Looking forward to the second half of the year, the economy has a bottom line, policies support the capital market, and the AI industry's progress is expected to drive the long - term bullishness of the capital market [19]. 2. Fund Performance: Past Managed Funds Achieved Excess Returns of 75.05% in a Bear Market, and Currently Managed Funds Continue the Excellent Historical Performance 2.1 Overview of the Fund Manager's Managed Fund Performance - As of the end of the second quarter of 2025, Zhang Mingxin managed a total fund size of 4.241 billion yuan. The product YDZC - Taihe Preferred No. 2 achieved an excess return of 75.05% relative to the CSI 300 index from early 2021 to early 2025, ranking first among 68 similar products [21]. - Huashang Equal - Growth and Huashang Advantage Industry had excess returns of 67.07% and 57.18% respectively relative to similar funds as of September 22, 2025, and their performance rankings were among the top 0.86% and 1.25% in similar funds [22]. 2.2 Introduction to Fund Basic Information - Huashang Equal - Growth A (011369.OF) is a partial - stock hybrid fund. Zhang Mingxin took over on March 4, 2025, and the fund size was about 185 million yuan as of June 30, 2025 [24]. - Huashang Advantage Industry (000390.OF) is a flexible - allocation fund. Zhang Mingxin took over on March 12, 2025, and the fund size was about 4.055 billion yuan as of June 30, 2025 [25]. 3. Fund Performance: Currently Managed Products Have Outstanding Excess Performance, and Past Managed Products Had Positive Excess Returns in Each Full Year 3.1 Performance of Currently Managed Funds - Zhang Mingxin has strong performance - acquisition ability. From March 4, 2025, to September 22, 2025, Huashang Equal - Growth A had a fund return of 93.25%, ranking 37/4488 (top 0.82%) among similar funds, with an excess return of 71.23% relative to the benchmark [27]. - Huashang Advantage Industry A had a recent quarterly return of 79.29%, ranking 36/2326 (top 1.54%) among similar funds, with a Sharpe ratio of 4.83 [29]. 3.2 Historical Performance of Past Managed Products - From January 28, 2021, to January 19, 2025, the Taihe Preferred No. 2 product managed by Zhang Mingxin had positive excess returns in each full year, with excess returns of +22.69%, +29.48%, and +9.62% relative to the CSI 300 index in 2022, 2023, and 2024 respectively [33]. - Zhang Mingxin adheres to the investment idea based on fundamentals and industry trends, and achieved significant absolute and relative returns for clients by selecting booming growth industries during the volatile capital market from 2022 to 2024 [33]. 4. Source of Excess Returns: Significant and Positive Stock - Selection Ability and Strong Adaptability under Different Market Conditions and Value - Growth Style Dominance 4.1 Stock - Selection and Timing Ability of the Fund Manager - The T - M model is used to measure the stock - selection and timing ability of the fund manager. The analysis shows that the Taihe Preferred No. 2 fund showed significant and continuous positive stock - selection ability during certain periods [36][39]. 4.2 Strong Adaptability under Different Market Conditions and Value - Growth Style Dominance - The analysis shows that Zhang Mingxin showed strong adaptability under different market rise - fall ranges and different value - growth style dominance when managing the Taihe Preferred No. 2 fund, and had stronger adaptability to the small - cap style compared to the large - cap style [42][49]. 5. Conclusion - Zhang Mingxin is a fund manager with strong investment ability. His currently managed funds have excellent performance, and his past managed products also achieved good results. He is long - term optimistic about the AI industry and other sectors, and investors interested in relevant fields are recommended to pay attention to Huashang Equal - Growth, Huashang Advantage Industry, and Huashang Zhiyuan Return [50][52].

Core Viewpoint - Hong Kong Futures Exchange plans to launch futures contracts based on the Hang Seng Biotechnology Index on November 28, 2025, pending regulatory approval [1] Group 1: Futures Contract Details - The futures contract will be based on the Hang Seng Biotechnology Index, which tracks the 30 largest biotechnology companies listed in Hong Kong [1] - The contract code will be HBI, with each index point valued at 50 HKD, resulting in a contract value of approximately 776,000 HKD based on the closing price on October 14, 2025 [3] - The contract will have monthly, quarterly, and subsequent quarterly expirations, with cash settlement in HKD [3] Group 2: ETF Performance and Characteristics - The Hang Seng Biotechnology ETF (513280) has a management fee of 0.15% per year and has seen a significant net inflow of funds, with a year-to-date share growth rate of 24% [1][4] - The ETF's underlying index has a high concentration in innovative drugs (69%) and CXO (over 20%), providing exposure to high-growth sectors [4][6] - The index has shown a remarkable return of 79.67% over the past year, with the ETF outperforming the index with a return of 80.9% [6][10] Group 3: Market Context and Trends - The introduction of the Hang Seng Biotechnology Index futures reflects the growing importance of the biotechnology sector, paralleling the Hang Seng Technology Index [2] - The biotechnology sector is described as the fastest-growing and most dynamic segment in the market, indicating strong investor interest and potential for future growth [1][2] - Analysts are optimistic about the long-term trends in innovative drugs and the overall health of Hong Kong's pharmaceutical companies, supported by stable cash flows and robust R&D pipelines [9]

截至午间收盘 该指数涨跌 -2. 6% 截至午间收盘，科创板50指数下跌2.6%，科创综指下跌2.6%，科创100指数下跌3.1%，科创成长指数下跌3.3%。 Wind数据显示，截至昨日，科创板:01ETF （588080）近5个交易日合计净流入超5亿元，最新规模超730亿元，位居同类产品第一。 科创板系列指数基本情况跟踪 (2025年10月17日) 科创板50ETF ( 跟踪上证科创板50成份指数 该指数由科创板中市值大、流动性 截至午间收盘 该指数自 该指数 好的50只股票组成,"硬科技"龙 该指数涨跌 滚动市盈率 发布以来1 头特征显著,半导体占比超65%, 与医疗器械、软件开发、光伏设备 -2. 6% 181. 3倍 98. 行业合计占比近80% 科创100ETF易方达 跟踪上证科创板100指数 该指数由科创板中市值中等且流动 截至午间收盘 该指数 性较好的100只股票组成,聚焦中 该指 该指数涨跌 滚动市盈率 小科创企业,电子、医药生物、电 力设备、计算机行业合计占比超 2023年1 -3. 1% 275.5倍 80%,其中电子、医药生物行业占 发: 比较高 科创综指ETF易方达 跟踪上证科创板综合 ...

Group 1 - The company, Jianfa Zhixin (301584.SZ), confirmed that its main business involves the distribution and direct sales of medical devices, such as high-value medical consumables and IVD diagnostic products [2] - The company does not engage in the sales of innovative drug projects [2]

Investment Rating - The report maintains a positive outlook on Hansoh Pharmaceutical, indicating an expectation of outperforming the market in the next 12-18 months [15]. Core Insights - Hansoh Pharmaceutical has entered into a licensing agreement with Roche for HS-20110 (CDH17 ADC), which includes an upfront payment of USD80 million and potential milestone payments of up to USD1.45 billion, along with royalties on product sales [5][6]. - The company anticipates significant growth in milestone revenues and out-licensing opportunities, with management raising the full-year revenue guidance to mid-to-high double-digit growth [6][7]. - Revenue from innovative drugs is projected to exceed CNY10 billion in 2025, with innovative drug revenue likely surpassing 80% of total revenue [6][7]. - The core product Aumolertinib is expected to achieve sales exceeding CNY6 billion in 2025, with peak sales potential reaching CNY8 billion [7]. Summary by Sections Licensing Agreement - Hansoh has licensed HS-20110 (CDH17 ADC) to Roche, receiving an upfront payment of USD80 million and up to USD1.45 billion in milestone payments tied to development and commercialization [5][6]. Revenue Growth - The company’s milestone revenues for the first half of 2025 have significantly exceeded expectations, prompting an upward revision of the revenue guidance [6]. - Combined milestone and upfront payments are projected to exceed CNY2.2 billion [6]. Product Pipeline - Aumolertinib has received approval for four indications, with anticipated sales growth and further approvals expected to solidify its market position [7]. - The early-stage pipeline includes innovative molecules like EGFR/cMET ADC and CDH6 ADC, which present out-licensing opportunities [6].